Xinliang Zhang, Narasimha M. Beeraka, Mikhail Y. Sinelnikov, Oleg S. Glazachev, Konstantin S. Ternovoy, Pengwei Lu, Aida Isaeva, Yu Cao, Jin Zhang, Arshia Bakhtiari Nezhad, Maria Plotnikova and Kuo Chen* Pages 63 - 70 ( 8 )
<p>Background: Post-mastectomy lymphedema is a chronic progressive disease characterized by a significant reduction in quality of life and a range of complications. <p> Aim: To this date, no single treatment method provides pathological correction of the mechanisms associated with tissue reorganization observed in later-stage breast cancer-related lymphedema (BCRL). <p> Methods: To define a personalized approach to the management of patients with iatrogenic lymphedema, we performed a systematic review of literature without a comprehensive meta-analysis to outline existing molecular- genetic patterns, overview current treatment methods and their efficacy, and highlight the specific tissue-associated changes in BCRL conditions and other bio-engineering approaches to develop personalized therapy. <p> Results: Our results show that several tissue-specific and pathological molecular markers may be found, yet current research does not aim to define them. <p> Conclusion: As such, currently, a strong foundation for further research into molecular-genetic changes in lymphedema tissue exists, and further research should focus on finding specific targets for personalized treatment through bio-engineering approaches.</p>
Lymphedema, lymphatic system pathology, breast cancer, anti-BCRL therapies, bioengineering approaches, chronic progressive disease.